Cardiogenic shock with systemic inflammatory response: Complications of acute myocardial infarction
Authors:
Janda Robert 1; Sýkora Roman 1,2
Authors‘ workplace:
Jednotka intenzivní péče, Anesteziologicko-resuscitační oddělení, Karlovarská krajská nemocnice, a. s.
1; Lékařská fakulta Plzeň, Univerzita Karlova v Praze
2
Published in:
Anest. intenziv. Med., 21, 2010, č. 1, s. 14-17
Category:
Intensive Care Medicine - Review Article
Overview
The mortality of cardiogenic shock remains high despite current progress in revascularisation and the supportive treatment of myocardial infarction. An activation of systemic inflammation may appear in one fifth of the cases of cardiogenic shock and as such may further increase the risk of death.
Keywords:
acute myocardial infarction – SIRS – cardiogenic shock
Sources
1. Babaev, A. et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA, 2005, 294, p. 448–454.
2. Fox, K. A. et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk charakteristics? The Global Registry of Acute Coronary Events (GRACE). Heart, 2007, 93, p. 177–182.
3. Hochman, J. S. et SHOCK Investigators Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med., 1999, 341, p. 625–634.
4. Kohsaka, S. et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch. Intern. Med., 2005, 165, p. 1643–1650.
5. Hochman, J. S. et al. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation, 2003, 107, p. 2998–3002.
6. Cotter, G. et al. Cardiogenic shock- beyond the large infarction. Crit. Care Med., 2006, 34, p. 2234–2235.
7. Armstrong, P. W. et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA, 2007, 297, p. 43–51.
8. Alexander, J. H. et TRIUMPH Investigators Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA, 2007, 297, p. 1657–1666.
9. Reynolds, H. R. et al. Cardiogenic shock: Current Concepts and Improving Outcomes. Circulation, 2008, 117, p. 686–697.
10. Kohsaka, S. et al. High incidence of sepsis complicating cardiogenic shock following acute myocardial infarction. Circulation, 2001, 104, p.II–483.
11. Geppert, A. et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit. Care Med., 2006, 34, p. 2035–2042.
12. Nicholls, S. J. et al. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation, 2007, 116, p. 2315–2324.
13. Mathey, D. et al. Early accumulation of the terminal complement - complex in the ischaemic myocardium after reperfusion. Eur. Heart J., 1994, 15, p. 418–423.
14. Deliargyris, E. N. et al. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am. J. Cardiol., 2000, 86, p. 913–918.
15. Neumann, F. J. et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation, 1995, 92, p. 748–755.
16. Wildhirt, S. M. et al. Involvement of inducible nitric oxide synthetase in the inflammatory process of myocardial infarction. Int. J. Cardiol., 1995, 50, p. 253–261.
17. Yamauchi-Tahikara, K. et al. Hypoxic stres induces cardiac myocyte-derived interleukin-6. Circulation, 1995, 91, p. 1520–1524.
18. Brunkhorst, F. M. et al. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation. Int. J. Cardiol., 1999, 72, p. 3–10.
19. Theroux, P. et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: substudy of the COMMA trial. Eur. Heart J., 2005, 26, p. 1964–1970.
20. Zhang, C. et al. TNF-alfa contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol., 2006, 26, p. 475–480.
21. Debrunner, M. et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin. Res. Cardiol., 2008, 97, p. 298–305.
22. Granger, C. B. et al. Pexelizumab, an anti- C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation, 2003, 108, p. 1184–1190.
23. de Werra, I. et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit. Care Med., 1997, 25, p. 607–613.
24. Flesch, M. et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J. Pharmacol. Exp. Ther., 1997, 281, p. 1340–1349.
25. Ulmans, J. G. et al. Nitric oxide in the regulation of blood flow and arterial pressure. Annu. Rev. Physiol., 1995, 57, p. 771–790.
26. Nijveldt, R. J. et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr., 2003, 22, p. 23–30.
27. Cotter, G. et al. L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study. Eur. Heart J., 2003, 24, p. 1287–1295.
28. Cotter, G. et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in treatment of cardiogenic shock. Circulation, 2000, 101, p. 1358–1361.
29. Dzavik, V. et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur. Heart J., 2007, 28, p. 1109–1116.
30. Bailey, A. et al. The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here? Am. J. Cardiovac. Drugs, 2007, 7, p. 337–345.
31. Teerlink, T. Tilarginine in patients with acute myocardial infarction and cardiogenic shock. JAMA, 2007, 298, p. 971–972.
32. Kohsaka, S. et al. SHOCK Investigators Microbiological profile of septic complications in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK study). Am. J. Cardiol., 2007, 15, 99, p. 802–804.
33. Bochicchio, G. V. et al. Systemic inflammatory response syndrome score at admission independently predicts infection in blunt trauma patients. J. Trauma, 2001, 50, p. 817–820.
34. Hoover, L. et al. Systemic inflammatory response syndrome and nosocomial infection in trauma. Journal Trauma Injury Infect Critical Care, 2006, 61, p. 310–317.
35. Rau, M. B. et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT). Annals of Surgery, 2007, 245, p. 745–754.
36. Tang, B. M. P. et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis., 2007, 7, p. 210–217.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2010 Issue 1
Most read in this issue
- Osmotherapy in neurosurgery – hyperosmolar mannitol or hypertonic saline?
- Ultrasound guidance in regional anaesthesia and interventional pain management
- The development of paediatric anaesthesiology and intensive therapy in Prague
- Immunotherapy of sepsis